Home/Pipeline/Standalone Seasonal Influenza Vaccine

Standalone Seasonal Influenza Vaccine

Seasonal Influenza

Phase 3ActiveNCT06313320

Key Facts

Indication

Seasonal Influenza

Phase

Phase 3

Status

Active

Company

Novavax

About Novavax

Novavax is a mission-driven biotech focused on discovering, developing, and commercializing innovative protein-based vaccines to address serious infectious diseases. Its core achievement is the successful global commercialization of Nuvaxovid®, a COVID-19 vaccine, validating its integrated technology platform of recombinant nanoparticle antigens and the Matrix-M adjuvant. The company's strategy centers on advancing a high-value pipeline in influenza and other infectious diseases while pursuing strategic partnerships and exploring new applications for its adjuvant technology in areas like oncology to drive long-term growth.

View full company profile

Therapeutic Areas

Infectious Diseases Oncology (Exploratory)

Other Seasonal Influenza Drugs

Drug	Company	Phase	Status
mRNA-based Influenza Vaccine	Sanofi	Phase 3	Active
mRNA-1010/1011	Moderna	Phase 3	Active
LUNAR®-FLU (ARCT-2138)	Arcturus Therapeutics	Phase 1	Status Unknown
Oral Influenza Vaccine	Vaxart	Phase 2	Active